[
    [
        {
            "time": "2019-11-28",
            "original_text": "重磅！医保谈判爆出大利好，救命药最高降60%！",
            "features": {
                "keywords": [
                    "医保谈判",
                    "降价",
                    "利好",
                    "救命药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "重磅！医保谈判爆出大利好，救命药最高降60%！",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "医保谈判结果公布，利好国产创新企业",
            "features": {
                "keywords": [
                    "医保谈判",
                    "国产创新",
                    "利好"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医保谈判结果公布，利好国产创新企业",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "PD-1医保谈判生变：君实疑似落选，外资持续观望，恒瑞笑了？",
            "features": {
                "keywords": [
                    "PD-1",
                    "医保谈判",
                    "君实",
                    "恒瑞",
                    "外资"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "PD-1医保谈判生变：君实疑似落选，外资持续观望，恒瑞笑了？",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "【科新先声】2019年国家医保药品目录调整工作结束，有哪些亮点？【安信诸海滨团队】",
            "features": {
                "keywords": [
                    "医保药品目录",
                    "调整",
                    "亮点"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【科新先声】2019年国家医保药品目录调整工作结束，有哪些亮点？【安信诸海滨团队】",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "2019年国家医保谈判准入药品名单公布 机构建议关注创新药领域",
            "features": {
                "keywords": [
                    "医保谈判",
                    "准入药品",
                    "创新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2019年国家医保谈判准入药品名单公布 机构建议关注创新药领域",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "医保局“为民砍价”火了，降价超60%！这些A股公司“中标”，百亿“聪明钱”提前埋伏！",
            "features": {
                "keywords": [
                    "医保局",
                    "降价",
                    "A股",
                    "中标"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医保局“为民砍价”火了，降价超60%！这些A股公司“中标”，百亿“聪明钱”提前埋伏！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-11-28",
            "original_text": "降价63%成为唯一进医保的PD-1 信达生物股价微跌",
            "features": {
                "keywords": [
                    "降价",
                    "PD-1",
                    "信达生物",
                    "医保"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "降价63%成为唯一进医保的PD-1 信达生物股价微跌",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]